A Study of QL1706 Combined with Nine HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer

NCT06882447 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Cervical Cancer Stage IVB

Interventions

DRUG: Trial drug: QL1706, HPV 9-valent vaccine

Sponsor

Northern Jiangsu People's Hospital